Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 550 of 2873 entries
View as:

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03008408 Org: User:
Start: 08/18/17 End: 08/31/28 Due: 08/31/29

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Phase: N/A Priority: Normal
NCT ID: NCT04216524 Org: User:
Start: 05/29/20 End: 12/31/26 Due: 12/31/27

Radiologic Pathologic Correlation of Imaging to Distinguish True Progression From Pseudoprogression in Brain Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06199479 Org: User:
Start: 06/04/24 End: 10/31/25 Due: 10/31/26

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Phase: N/A Priority: Normal
NCT ID: NCT01469247 Org: User:
Start: 12/07/11 End: 09/20/22 Due: 09/20/23

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

Phase: N/A Priority: Normal
NCT ID: NCT02962661 Org: User:
Start: 07/18/20 End: 07/30/25 Due: 07/30/26

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Phase: N/A Priority: Normal
NCT ID: NCT05977998 Org: User:
Start: 09/08/23 End: 10/31/30 Due: 10/31/31

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02321501 Org: User:
Start: 06/22/16 End: 12/31/26 Due: 12/31/27

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

Phase: N/A Priority: Normal
NCT ID: NCT05357794 Org: User:
Start: 10/13/22 End: 01/30/26 Due: 01/30/27

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT06445907 Org: User:
Start: 02/12/25 End: 07/01/28 Due: 07/01/29

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02846623 Org: User:
Start: 01/31/17 End: 02/28/27 Due: 02/28/28

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT02661282 Org: User:
Start: 06/01/16 End: 02/23/22 Due: 02/23/23

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Phase: N/A Priority: Normal
NCT ID: NCT05873699 Org: User:
Start: 08/18/23 End: 01/31/27 Due: 01/31/28

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03101748 Org: User:
Start: 01/29/18 End: 05/13/25 Due: 05/13/26

Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)

Phase: N/A Priority: Normal
NCT ID: NCT02263014 Org: User:
Start: 02/24/14 End: 04/30/28 Due: 04/30/29

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04615013 Org: User:
Start: 11/23/20 End: 10/31/25 Due: 10/31/26

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase: N/A Priority: Normal
NCT ID: NCT06358430 Org: User:
Start: 12/02/24 End: 01/18/29 Due: 01/18/30

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

Phase: N/A Priority: Normal
NCT ID: NCT06617858 Org: User:
Start: 12/04/24 End: 02/01/28 Due: 02/01/29

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00227656 Org: User:
Start: 09/30/05 End: 11/30/06 Due: 11/30/07

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04458610 Org: User:
Start: 05/26/20 End: 05/26/26 Due: 05/26/27

Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

Phase: N/A Priority: Normal
NCT ID: NCT06083883 Org: User:
Start: 03/27/24 End: 11/30/28 Due: 11/30/29

Impact of High Dietary Fiber on Microbiome and Vaccine Responses

Phase: N/A Priority: Normal
NCT ID: NCT05565586 Org: User:
Start: 08/23/22 End: 01/02/29 Due: 01/02/30

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05985954 Org: User:
Start: 01/18/24 End: 03/28/28 Due: 03/28/29

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03586609 Org: User:
Start: 10/25/18 End: 04/30/27 Due: 04/30/28

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00506155 Org: User:
Start: 06/30/07 End: 08/31/14 Due: 08/31/15

Safety Evaluation of Intra-Operative MRI-Based Guidance for Laser Ablation of Epidural Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT02613390 Org: User:
Start: 12/18/15 End: 10/17/18 Due: 10/17/19